Меню
Идёт набор NCT06744322

Fast Discharge After Acute Myocardial Infarction Discharge MI

Без фазы С лечением Acute Myocardial Infarction (AMI)

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Fast discharge strategy.
Кому может быть актуально
Состояния в реестре: Acute Myocardial Infarction (AMI). Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Австрия, Германия
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Fast Discharge After Acute Myocardial Infarction Discharge MI - A Randomized Multicenter Non Inferiority Trial

Обзор

To evaluate the hypothesis that a fast discharge strategy (discharge at 24 \[± 12\] hours) following invasive management for acute myocardial infarction is non-inferior to standard of care (\>36 hours) with respect to the risk of major adverse cardiovascular events (MACE) during follow-up.

Подробное описание

The goal of this randomized, multicenter trial is to assess the safety of a fast discharge strategy following acute myocardial infarction as compared to standard of care. The trial will evaluate the hypothesis that a fast discharge strategy (discharge at 24 \[± 12\] hours) following invasive management of acute myocardial infarction is non-inferior to standard of care (discharge \>36 hours) with respect to the risk of major adverse cardiovascular events at 12 months.

Вмешательства

  • Процедура Fast discharge strategy
    Patients undergoing invasive management after myocardial infarction will be discharged after 24 (+/- 12) hours.

Первичные конечные точки

  • MACE [Срок оценки: From the date of randomization until the first documented event during the follow-up period (up to 12 months).]
Вторичные конечные точки (12)
  • All cause death [Срок оценки: From the date of randomization until the first documented event during the follow-up period (up to 12 months).]
  • Number of participants with myocardial re-infarction [Срок оценки: From the date of randomization until the first documented event during the follow-up period (up to 12 months).]
  • Number of participants with unscheduled cardiovascular re-hospitalization [Срок оценки: From the date of randomization until the first documented event during the follow-up period (up to 12 months).]
  • Number of participants with Cardiovascular death [Срок оценки: From the date of randomization until the first documented event during the follow-up period (up to 12 months).]
  • Number of participants hospitalized for heart failure [Срок оценки: From the date of randomization until the first documented event during the follow-up period (up to 12 months).]
  • Number of participants expiring hospitalization from any cause [Срок оценки: From the date of randomization until the first documented event during the follow-up period (up to 12 months).]
  • Number of patients experiencing a stroke [Срок оценки: From the date of randomization until the first documented event during the follow-up period (up to 12 months).]
  • Number of participants with a bleeding event [Срок оценки: From the date of randomization until the first documented event during the follow-up period (up to 12 months).]
  • Healthcare costs per patient between randomization and 12 months [Срок оценки: From the date of randomization until the first documented event during the follow-up period (up to 12 months).]
  • Length of hospital stay [Срок оценки: From the date of randomization to the date of hospital discharge, for up to 100 days]
  • Percentage of patients on guideline-directed therapy [Срок оценки: From the date of randomization until the first documented event during the follow-up period (up to 12 months).]
  • Infection [Срок оценки: At 30 days]

Критерии участия

Критерии включения

  • Uncomplicated acute myocardial infarction (NSTEMI and STEMI) diagnosed according to the 2023 acute coronary syndrome guidelines of the ESC
  • Age ≥ 18 years at time of consent
  • Invasive management strategy and in case of PCI successful intervention of the culprit lesion defined by post-interventional TIMI 3 flow
  • Ability to understand and willingness to sign and date written informed consent

Критерии исключения

  • Myocardial infarction complicated by cardiac arrest (out-of-hospital cardiac arrest/in-hospital cardiac arrest)
  • PCI-related complications (coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, allergic reaction grade ≥2, stroke/thromboembolism, access site complications including pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage and arterial dissection/occlusion or emboli)
  • Malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (< 50 beats per minute due to sinus node or atrioventricular conduction system abnormalities, second- /third-degree atrioventricular block) after PCI
  • Ongoing hemodynamic instability (systolic blood pressure <90 mmHg, elevated lactate concentrations, need for inotropes or vasopressors)
  • Ongoing respiratory instability defined by Killip class >I (rales, pulmonary edema)
  • Ongoing quantitative disorders of consciousness (somnolence, sopor, coma)
  • Acute kidney injury defined by Kidney Disease Improving Global Outcomes (KDIGO) stages 2 and 3
  • Pregnancy
  • Untreated critical non-culprit lesions requiring revascularization during index hospitalization not allowing fast discharge
  • Immobility/limited mobility or social circumstances that prevent fast discharge assessed by an interprofessional care team

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Простое слепое
Основная цель
Другое

Центры проведения

Австрия · 7 центров
  • Hospital Wiener Neustadt — Wiener Neustadt
  • Cardinal Schwarzenberg Hospital Schwarzach — Schwarzach im Pongau
  • Paracelsus Medical University Salzburg — Salzburg
  • Medical University of Graz — Graz
  • Medical University of Innsbruck — Innsbruck
  • University Teaching Hospital Wels-Grieskirchen — Wels
  • Academic Teaching Hospital Feldkirch — Feldkirch
Германия · 1 центр
  • Ludwig Maximilian University Munich — Munich

Идентификаторы

NCT: NCT06744322 · 1284/2024 · 20241113-3609

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗